IQVIA Holdings Inc. Emerges as a Leader in Decentralized Clinical Trials

On March 10, 2025, IQVIA Holdings Inc. (NYSE:IQV), a prominent global provider of AI-powered analytics and clinical research services, proudly announced its recognition as a leader in the IDC MarketScape's 2024 Vendor Assessment for Decentralized Clinical Trial (DCT) technologies and consulting services. This achievement underscores IQVIA's commitment to advancing clinical trial methodologies through innovative technology solutions and expert consulting.

The IDC MarketScape report highlights the growing importance of decentralized clinical trials, which have gained significant traction since the onset of the COVID-19 pandemic. These trials utilize telemedicine and digital technologies to facilitate trial activities outside traditional clinical sites. By enabling remote patient monitoring through wearable devices and digital communication tools, DCTs minimize the necessity for patients to visit trial locations, thereby enhancing participation and data collection.

Dr. Nimita Limaye, IDC’s Research Vice President for Life Sciences R&D Strategy and Technology, noted that decentralized trials are not a fleeting trend but rather a strategic shift toward a "business as usual" approach in clinical research. She emphasized the industry’s evolving perception of DCTs, stating, “The focus is on integration of technologies and touchpoints to create unified and meaningful experiences.”

IQVIA's extensive experience and robust capabilities in decentralized clinical trials position it as a significant player in the life sciences sector. With over 200 specialized DCT consultants and a wide array of DCT-enabling technologies, IQVIA offers deep expertise in clinical and DCT implementation strategies across various therapeutic areas and trial phases.

According to the IDC report, IQVIA excels in providing insights on country-specific regulatory strategies for DCT implementation and business process transformations necessary for adopting DCT models. Furthermore, the company emphasizes the role of AI in enhancing the overall patient experience, employing novel Generative AI (GenAI) tools to further this goal.

Susan Hill, Senior Vice President of Product Management for Digital Products & Solutions at IQVIA, expressed pride in the company’s leadership position in decentralized clinical trials. She stated, "We remain focused on delivering cutting-edge technology solutions that enhance patient and site experiences and drive healthcare forward."

Alison Liddy, Senior Vice President for Patient and Site Centric Solutions, echoed this sentiment, stating, “Being named a Leader in the IDC MarketScape report highlights our commitment to revolutionizing clinical trials through innovation and excellence. We are honored to receive this distinction and empower our customers to achieve outstanding results."

The IDC MarketScape report represents the first comprehensive assessment of both DCT technology solutions and consulting services within the life sciences R&D space. The evaluation criteria included a vendor's capabilities, strategic initiatives, and factors contributing to market success. This recognition not only reinforces IQVIA's position as an industry leader but also signals the company's readiness to meet the evolving demands of clinical research.

As decentralized clinical trials become an integral part of the healthcare landscape, IQVIA Holdings Inc. is at the forefront of this transformation. With a strong focus on technological integration, regulatory expertise, and patient-centric solutions, IQVIA is well-equipped to continue driving innovation in clinical trials and improving patient outcomes on a global scale. As the industry evolves, IQVIA's commitment to excellence and leadership in DCTs positions it as a key player in the future of life sciences research.